Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. by Pectasides, D. et al.
Br.~~
J.Cne 18) 0 2 2 TeMcilnPesLd,18
Treatment of metastatic malignant melanoma with dacarbazine, vindesine
and cisplatin
D. Pectasides, H. Yianniotis, N. Alevizakos, D. Bafaloukos, V. Barbounis, J. Varthalitis, M.
Dimitriadis & A. Athanassiou
First Department ofMedical Oncology, The Metaxas Memorial Cancer Hospital, 51 Botassi Street, Piraeus 18537, Greece.
Summary Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin
(CDDP) 120 mg m 2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on
days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity.
There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of
45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high
rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
There is documented activity of vindesine (VDS) (Retsas et
al., 1980) and dacarbazine (DTIC) (Comis, 1976; Constanzi,
1976; Pritchard et al., 1981) as single agents or in combina-
tion in malignant melanoma with objective response rates of
15-42% (Einhorn et al., 1974; Hill et al., 1984; Retsas et al.,
1985). Numerous attempts have been made to increase the
response rate by combining various drugs. However, there is
no evidence that any particular combination has improved
these results (Einhorn et al., 1974; Karakousis et al., 1979).
Cisplatin (CDDP) alone or in combination with other active
agents has been tried in patients with advanced malignant
melanoma and has resulted in a wide range of remission rates
(Chary et al., 1977; Nathanson et al., 1981; Al-Sarraf et al.,
1982; York et al., 1983; Retsas et al., 1985; Wussow et al.,
1987).
Since DTIC, VDS and CDDP have different mode of
action and toxicity, it was rational to combine these drugs in
an effort to improve response rates and possibly response
duration.
Table I Patient characteristics
Characteristic No. ofpatients (%)
Total no. entered 27
Sex
Male 14 (52)
Female 13 (48)
Age (years)
Mean 54
Median 57
Range 36-72
ECOG performance status
0 6 (22.3)
1 11 (40.7)
2 10 (37.0)
Site of metastases
Subcutaneous and skin 14 (52)
Lymph nodes 15 (56)
Lung 14 (52)
Liver 1 (4)
Bone 2 (8)
Patients and methods
From March 1984 to December 1986, 27 consecutive patients
entered the trial. Entry criteria included histologically
documented melanoma, age < 75 years, ECOG performance
status of 0-2, predicted survival > 2 months, no prior
chemotherapy and creatinine clearance > 60 ml min-'.
Chemotherapy consisted of CDDP 120 mg m-2 as a
30 min infusion in 3% hypertonic saline with hydration and
mannitol diuresis on day 1, VDS 3 mgm2 (no more than
5 mg) on day 2 as an i.v. bolus and DTIC 250 mgm2 on
days 2-6 as an i.v. infusion over 30 min. The course was
repeated every 4 weeks and doses were decreased according
to the degree of haematological and renal toxicity of the
preceding course.
Antiemetic treatment with metoclopramide 2 mg kg-' 0.5 h
before and 1.5, 3.5, 5.5 and 8 h after CDDP administration
plus dexamethasone 8 mg 3 h before and 3, 6 and 9 h after
CDDP administration was given. On days 2-6 metoclo-
pramide 2 mg kg-' plus dexamethasone 8 mg 0.5 h before
and 3 h after DTIC administration were given.
Fourteen males and 13 females with a mean age of 54
years entered the trial. Patient characteristics are shown in
Table I. The mean number of administered courses was four
(range 1-8 courses). World Health Organization (WHO)
response and toxicity criteria were used (WHO, 1979).
Results
Response to therapy
The response to therapy was as follows: complete response
(CR) five (19%) patients, partial response (PR) seven (26%),
stable (SD) or progressive disease (PD) 15 (55%). The
median duration of CR was 4 + months (4,4,4,4.5,9 +) and
of PR 8 months (3,4.5,5.5,8,10,11,18). Tumour responses by
site are shown in Table II. Metastases in the lungs, lymph
nodes, subcutaneous tissues and skin were more responsive
to chemotherapy. As shown in Table II, CRs were seen in
three patients with lung, subcutaneous and lymph node
metastases and in two patients with lung and lymph node
metastases. The seven patients responding partially to
chemotherapy were: one with lung metastases, one with lung
and lymph nodes metastases, two with subcutaneous and
skin disease, two with lymph nodes metastases and one with
lymph node, subcutaneous and skin metastases. There were
only four patients with visceral metastatic deposits. Of these
there were one PR and three SD or PD. Of the 12 patients
with non-visceral disease, five responded partially and seven
had SD or PD.
Toxicity
This schedule was well tolerated with moderate toxicity. The
toxic effects are summarised in Table III. Three patients
developed grade III and IV leucopenia and one of these
developed severe lung infection, which was successfully
treated with broad spectrum antibiotics. There were no
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Table II Metastatic sites
Subcutaneous Lung + Lung + Subcutaneous Subcutaneous
Subcutaneous Lymph skin + lymph subcutaneous Liver + Lung + skin + skin + lymph Response skin nodes Lung bones nodes skin lung bones lymph nodes nodes + lung Total
CR - - -- 2 - - - - 3 5 PR 2 2 1 - I - - - 1 - 7 SD or PD 3 2 1 1 2 2 1 1 2 15
Only visceral metastatic disease, 4: 1 PR, 3 SD or PD.
Only non-visceral metastatic disease, 12: 5 PR, 7 SD or PD.
Table III Toxicity
Grade
0 I II III IV
Anaemia 15 12 0 0 0
Leucopenia 9 7 8 2 1
Thrombocytopenia 23 3 1 0 0
nausea/vomiting 0 1 5 12 9
Nephrotoxicity 9 12 6 0 0
Neurotoxicity 25 2 0 0 0
Hearing impairement 27 0 0 0 0
treatment-related deaths. Despite hydration and mannitol
diuresis 18 patients developed transient and reversible
nephrotoxicity of grade I and II (increased urea and/or
creatinine). Two patients developed peripheral neuropathy,
with symptomatic paresthesias and sensory deficit. Nausea
and vomiting were nearly universal, but manageable. No
patient developed socially noticeable hearing loss.
Discussion
Although the prognosis of patients with disseminated malig-
nant melanoma remains poor, intensive chemotherapy may
produce remissions in a small number of patients. The
antitumour effect of VDS in advanced malignant melanoma
is at least comparable with, and probably superior to, DTIC
(Retsas et al., 1980). It has been reported that the response
rate in disseminated malignant melanoma with CDDP alone
or in combination with DTIC was no better than the rate
obtained with DTIC alone (Friedman et al., 1979; Oratz et
al., 1987).
The VBD (vinblastine, bleomycin, cisplatin) combination
has been reported to give objective responses ranging from
0% (York et al., 1983) to 43% (Nathanson et al., 1981).
Other investigators reported response rates in the
intermediate range 10-41% (Creagan et al., 1981; Canadian
Melanoma Group, 1984; Luikart et al., 1984; Mechl et al.,
1985). Carey et al. (1986) reported 25% CR + PR in
previously untreated patients with metastatic malignant
melanoma by using the VDD (vinblastine, dacarbazine, cis-
platin) regime. The (B) DPV3 (Retsas et al., 1985) (cisplatin,
vinblastine, vindesine ± bleomycin alternating with dacar-
bazine, vincristine) regime gave a 29% response rate despite
more advanced disease at the onset of treatment. It was
concluded that the addition of bleomycin to the DPV3 regime
had no effect on response.
The response rate of 45% (CR + PR) for DVP combin-
ation in our study is slightly lower than that recently
reported by Wussow et al. (1987). Toxicity encountered in
our patients was similar to those reported by Wussow et al.
(1987), who used an almost identical regime. The major
difference between the previous studies and the present one is
that they employed lower doses of cisplatin. Whether the
increased dose is important or whether our and Wussow et
al.'s (1987) better response rate was a chance occurrence
cannot be determined. The sites most likely to respond to
chemotherapy remain skin, lymph nodes and lungs and no
responses were observed in hepatic and skeletal metastases.
The DVP combination as first line chemotherapy in
disseminated malignant melanoma seems to yield a useful
response rate with moderate toxicity, but the mean duration
of response remains disappointing.
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